Compare Stocks: AFMD, KPRX, PHXM, and PBM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
KPRX Kiora Pharmaceuticals	$2.55	$2.57	$1.76 ▼ $2.95	$11.28M	-0.34	15,907 shs	4,490 shs
PBM Psyence Biomedical	$4.54 +2.5%	$3.47	$1.92 ▼ $34.63	$10.41M	1.72	86,975 shs	27,039 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
KPRX Kiora Pharmaceuticals	0.00%	-2.67%	-0.39%	+2.00%	-8.93%
PBM Psyence Biomedical	0.00%	+7.84%	+30.09%	+29.34%	-72.59%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
KPRX Kiora Pharmaceuticals	$2.55	$2.57	$1.76 ▼ $2.95	$11.28M	-0.34	15,907 shs	4,490 shs
PBM Psyence Biomedical	$4.54 +2.5%	$3.47	$1.92 ▼ $34.63	$10.41M	1.72	86,975 shs	27,039 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
KPRX Kiora Pharmaceuticals	0.00%	-2.67%	-0.39%	+2.00%	-8.93%
PBM Psyence Biomedical	0.00%	+7.84%	+30.09%	+29.34%	-72.59%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	1.00	Sell	N/A	N/A
PBM Psyence Biomedical	1.00	Sell	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AFMD, KPRX, PHXM, and PBM Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	PBM Psyence Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	$3.81 per share	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	$7.39 per share	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	N/A	N/A	N/A	-7,836.26%	-193.84%	-107.24%	N/A
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	11/6/2026 (Estimated)
PBM Psyence Biomedical	-$6.94M	$25.34	0.18	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest AFMD, KPRX, PHXM, and PBM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A
6/22/2026	Q4 2026	PBM Psyence Biomedical	N/A	-$0.41	N/A	-$0.4050	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
KPRX Kiora Pharmaceuticals	N/A	8.97	8.97
PBM Psyence Biomedical	N/A	14.62	14.62
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
KPRX Kiora Pharmaceuticals	76.97%
PBM Psyence Biomedical	77.44%
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
KPRX Kiora Pharmaceuticals	0.52%
PBM Psyence Biomedical	3.60%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	No Data
KPRX Kiora Pharmaceuticals	10	4.42 million	4.40 million	Not Optionable
PBM Psyence Biomedical	N/A	2.29 million	2.21 million	N/A
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

AFMD, KPRX, PHXM, and PBM Headlines

Recent News About These Companies

PHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJ

July 18, 2025 | wsj.com

Phaxiam Therapeutics SA (PHXM) Stock Forums - Investing.com

June 27, 2025 | investing.com

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 30, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, KPRX, PHXM, and PBM Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.55 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Psyence Biomedical NASDAQ:PBM

$4.54 +0.11 (+2.48%)

As of 09/4/2026 04:00 PM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 09/4/2026

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, KPRX, PHXM, and PBM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, KPRX, PHXM, and PBM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, KPRX, PHXM, and PBM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, KPRX, PHXM, and PBM Company Descriptions

Affimed NASDAQ:AFMD

Kiora Pharmaceuticals NASDAQ:KPRX

Psyence Biomedical NASDAQ:PBM

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, KPRX, PHXM, and PBM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, KPRX, PHXM, and PBM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, KPRX, PHXM, and PBM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, KPRX, PHXM, and PBM Company Descriptions

Affimed NASDAQ:AFMD

Kiora Pharmaceuticals NASDAQ:KPRX

Psyence Biomedical NASDAQ:PBM

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools